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Abstract
Evidence of the association between 25-hydroxyvitamin D (25(OH)D) and metabolic syndrome (MeS) remains uncertain and incongruent. This
study aimed to determine the association between 25(OH)D and MeS among Jordanian adults. A complex multistage sampling technique was used
to select a national population-based household sample. The present report deals exclusively with adults aged > 18 years who had complete information
on all components of MeS (n = 3,234). A structured questionnaire was used to collect all relevant information. Anthropometric, clinical, and laboratory 
measurements were obtained. MeS was defined according to the International Diabetes Federation (IDF) definition. Of the total, 42.0% had MeS
and 31.7% had 25(OH)D < 30 ng/ml. In a stratified analysis, the prevalence of MeS did not differ significantly between subjects with low and
normal 25(OH)D levels for men and women in all age groups. In the multivariate analysis, the odds of MeS were not significantly different between
subjects with low and normal 25(OH)D levels (OR = 0.85, 95% CI: 0.70, 1.05, P-value = 0.133). The association between 25(OH)D and MeS remained
non-significant when 25(OH)D was analyzed as a continuous variable (OR = 1.004, 95% CI; 1.000, 1.008, P= 0.057) and when analyzed based
on quartiles. None of the individual components of MeS were significantly associated with 25(OH)D level. This study does not provide evidence
to support the association between 25(OH)D level and MeS or its individual components. Prospective studies are necessary to better determine
the roles of 25(OH)D levels in the etiology of MeS.
Key Words: 25-hydroxyvitamin D, metabolic syndrome, obesity, adults, Jordan
Introduction7)
Vitamin D status is measured by circulating levels of 25- 
hydroxyvitamin D (25(OH)D), and which is the combined 
product of cutaneous synthesis from solar exposure and dietary 
sources. A high prevalence of vitamin D deficiency and insu-
fficiency was reported in different populations across the world 
[1-4]. Vitamin D plays an important role in bone mineralization 
and facilitates the intestinal absorption of calcium and phos-
phorus by both genomic and nongenomic mechanisms [5]. 
Furthermore, vitamin D plays a role in cancer prevention [6], 
immune regulation [7], and glucose homeostasis [8]. Low serum 
25(OH)D levels have been linked to some chronic diseases, 
including cancer [9,10], cardiovascular diseases [11,12], multiple 
sclerosis [13], diabetes mellitus, [14,15], and hypertension [16].
Insulin resistance has been considered a possible mechanism 
underlying the metabolic syndrome [17]. Previous research 
suggests that low vitamin D levels are associated with insulin 
resistance [18], β-cell dysfunction, and impaired insulin secretion 
and action [18,19]. Vitamin D was found to play a role in the 
regulation of lipolysis [20]. This might therefore contribute to 
the development of the metabolic syndrome. Recently, several 
cross-sectional studies [16,21-34] explored the association 
between 25(OH)D and metabolic syndrome (MeS). While some 
of these studies [21-30] showed an inverse association between 
25(OH)D level and MeS, other studies [31-34] did not support 
this association. Although there is an agreement amongst the 
majority of study results on the presence of a association between 
25(OH)D and MeS, the evidence remains uncertain and 
incongruent. Studies have differed substantially in terms of 
methodology, populations studied, study design, as well as 
reporting, measuring, and analysis of 25(OH)D. Some of these 
studies did not adjust for important variables with putative 
associations to MeS such as parathyroid hormone (PTH) and 
calcium and magnesium, which are of great importance because 
elevated levels of PTH and hypomagnesemia were reported to 
be associated with MeS [24,35]. Furthermore, some studies were 
limited by restricted age variability and a lack of representation 
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of the general population. 
Since both MeS and vitamin D deficiency are highly prevalent 
worldwide, establishing an association between them may poten-
tially have wide public health implications. The objective of this 
study was to determine the association between 25(OH)D and 
MeS among a nationally representative sample of Jordanian adults. 
Subjects and Methods
Sampling
A national population-based household sample was selected 
from the 12 governorates of Jordan. These 12 governorates 
belong to the three regions of the country, namely, the north, 
middle, and south. A complex multistage sampling technique was 
used to select the households, taking into consideration the 
geographic distribution of the population as well as the urban- 
rural residence. Since the population is covered by an extensive 
network of health centers and because the study procedures had 
to take place in a medical setting, the selection households were 
health center-oriented. The health director in each governorate 
was contacted and asked to identify at least two health centers 
in which to conduct the study procedures. He was asked to select 
the health centers so that urban and rural areas in each 
governorate were represented and the selected centers had enough 
space to host the study team, participants, and equipment. A total 
of 31 health centers were identified and people served by these 
centers were targeted. A systematic sample of households was 
selected from the population served by the selected health centers. 
The number of selected households was approximately propor-
tional to the population in each region. 
In each selected area, one day before data collection, 2- 
membered teams (a male and a female each) visited the selected 
households, explained the purpose of the study, and invited all 
members aged ≥7 years to attend the health center in the next 
day after an overnight fast. Subjects on regular medications were 
asked to not take their medications early in that day, and to bring 
all their medications with them to the survey site. To encourage 
participation, the study team worked every day of the week 
including official holidays with the exception of Fridays during 
the entire study period. Of the 9,000 subjects invited to participate, 
5,640 subjects (1,607 males and 4,033 females) aged between 
7 and 90 years responded. The overall response rate was 63% 
(36% for males and 90% for females). The main reason for no 
response was lack of time due to being at work. 
The present report deals exclusively with adults aged > 18 
years who had complete information on all individual components 
of MeS (n = 3,234). 
Data collection
All field work was carried out between July 1
st and November 
30, 2009. Because of Ramadan (the fasting month for Muslims) 
and the following holidays, field work stopped for about 6 weeks 
during the period of August 20 to September 30, 2009. Thus, 
data collection was carried out during summer and autumn. 
Participants attended the health centers in the morning (8-11 am) 
with a minimum fasting time of 10 hours. 
A pilot-tested structured questionnaire was prepared and 
administered by trained interviewers to collect relevant informa-
tion that was necessary to answer the current research question 
and other selected research questions that will be addressed in 
separate publications. The questionnaire sought information on 
demographics, medical history, and factors potentially influencing 
serum 25(OH)D concentrations including highest level of 
education obtained, average monthly family income, amount of 
exercise per week, and smoking habits.
Two questions related to physical activity were modified from 
the Leisure Time Exercise Questionnaire to assess the physical 
activity of participants [36]. The two questions individually 
assessed moderate and vigorous activity by asking, "In the past 
week, how many hours did you spend doing moderate activity" 
and "In the past week, how many hours did you spend doing 
vigorous activity". More than 10 examples of common specific 
activities were given after each question. 
Anthropometric and clinical measurements 
Anthropometric measurements including weight, height, and 
hip and waist circumferences, were measured with the subjects 
wearing light clothing and no shoes [37]. Waist circumference 
was measured to the nearest centimeter using a non-stretchable 
tailor measuring tape at the midpoint between the bottom of the 
rib cage and above the top of the iliac crest during minimal 
respiration. Hip circumference was measured at the widest part 
of the body below the waist. Body mass index (BMI) was 
calculated as the ratio of weight in kilograms to the square of 
height in meters. Readings of systolic (SBP) and diastolic blood 
pressure (DBP) were taken with a subject seated and the arm 
at heart level, after at least 5 minutes of rest, using a standardized 
mercury sphygmomanometer. 
Laboratory analysis
For laboratory analysis and all biochemical measurements, two 
sets of fasting blood samples were drawn from a cannula inserted 
into the antecubital vein, into sodium fluoride potassium oxalate 
tubes for glucose and lithium heparin vacuum tubes for lipids. 
The samples were centrifuged at 3,000 rpm for 10 min within 
1 hour at the survey site, and the plasma was transferred to 
separate labeled tubes and placed immediately in cold boxes 
filled with ice and taken to the central laboratory of the National 
Center for Diabetes and Endocrinology. All biochemical mea-
surements were carried out by the same team of laboratory 
technicians and by using the same method throughout the study 134 Vitamin D deficiency and metabolic syndrome
Variable
Metabolic syndrome 
(IDF definition) Total
 N (%) P-value
Absent
N (%)
Present
N (%)
Sex 0.611
Male 456 (24.3) 320 (23.5) 776 (24.0)
Female 1,419 (75.7) 1,039 (76.5) 2,458 (76.0)
Age group < 0.005
19-39 1,165 (62.1) 320 (23.5) 1,485 (45.9)
40-59 602 (32.1) 756 (55.6) 1,358 (42.0)
≥60 108 (5.8) 283 (20.8) 391 (12.1)
Years of education  < 0.005
illiterate 75 (4.0) 207 (15.4) 282 (8.8)
< 12 year 526 (28.1) 537 (39.9) 1,063 (33.1)
12 year 546 (29.2) 287 (21.3) 833 (25.9)
> 12 year 722 (38.6) 314 (23.3) 1,036 (32.2)
Marital status < 0.005
Not married 379 (20.3) 60 (4.4) 439 (13.6)
Married 1,488 (79.7) 1,299 (95.6) 2,787 (86.4)
Income (JD), 1 JD = 0.71 US $ < 0.005
< 300 800 (43.1) 691 (51.4) 1,491 (46.6)
≥300 1,056 (56.9) 654 (48.6) 1,710 (53.4)
Smoking 0.034
No 1,484 (79.3) 1,102 (81.3) 2,586 (80.1)
Past 75 (4.0) 68 (5.0) 143 (4.4)
Current  313 (16.7) 186 (13.7) 499 (15.5)
Body mass index (kg/m
2)< 0 . 0 0 5
Normal 653 (34.8) 29 (2.1) 682 (21.1)
Overweight 721 (38.5) 332 (24.5) 1,053 (32.6)
Obesity 500 (26.7) 996 (73.4) 1,496 (46.3)
Region 0.001
North 206 (11.0) 184 (13.5) 390 (12.1)
Middle 1,200 (64.0) 908 (66.8) 2,108 (65.2)
South 469 (25.0) 267 (19.6) 736 (22.8)
Table 1. Socio-demographic and relevant characteristics of participants 
according to the status of metabolic syndrome 
period.
Serum 25(OH)D concentrations were determined by radioimm-
unoassay (BIOSOURCE Europe S.A., Nivelles, Belgium) [38]. 
The intra- and inter-assay coefficients of variation (CVs) values 
were 5.6% and 11%, respectively. The limit of detection was 
0.6 ng/ml. Serum intact PTH level was measured with a 
electrochemiluminscence (ECLIA-PTH) assay (Roche Diagnostics, 
Manheim, Germany) [39]. The detection limit of the assay was 
1.2 pg/mL, and the intra- and inter- assay coefficients of variation 
were below 5%. Creatinine, lipid parameters (total cholesterol, 
HDL, LDL, and triglycerides (TG)), and glucose were analyzed 
for all samples using enzymatic assays. Calcium was determined 
using the Scharzenbach method with o-cresolphthalein complexon. 
Magnesium was determined by a colorimetric method using 
chlorophosphonaxo III and phosphorous was determined by 
direct reduction of phosphomolybdate on a Cobas-800 analyzer 
(reagents supplied by Roche Diagnostics, Germany). The assays 
were conducted according to the manufacturers’ instructions. 
Other laboratory analyses were also performed for several blood 
constituents, but these are not described here because they are 
irrelevant to the current report.
Definition of variables
The subjects were classified as vitamin D-deficient on the basis 
of 25(OH)D concentrations of < 30 ng/mL (75 nmol per liter). 
MeS was defined according to the International Diabetes 
Federation (IDF) definition [40]. According to the IDF definition,
 
a person was defined as having MeS if he or she had central 
obesity (defined as waist circumference ≥94 cm for men and 
≥80 cm for women, with ethnicity specific values for other 
groups) plus any two of the following four factors: 1) Raised 
TG level: ≥150 mg/dL (1.7 mmol/L), or specific treatment for 
this lipid abnormality, 2) Reduced HDL cholesterol: < 40 mg/dL 
(1.03 mmol/L) in males and < 50 mg/dL (1.29 mmol/L) in 
females, or specific treatment for this lipid abnormality, 3) Raised 
blood pressure: systolic BP ≥130 or diastolic BP ≥85 mm Hg, 
or treatment of previously diagnosed hypertension, 4) Raised 
fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes. 
Data management and statistical analysis 
The data were entered into a computer using the Statistical 
Package for Social Sciences software, SPSS (SPSS Inc., Chicago, 
IL, USA) version 15. Participant characteristics were compared 
according to MeS status using χ
2 tests for categorical variables. 
One-way analysis of variance (ANOVA) was used to compare 
the means of anthropometric and clinical characteristics across 
quartiles of 25(OH)D levels for men and women. Age-standardized 
rates of MeS were calculated using the world population as a 
standard population. 
Multivariable logistic regression models were fit to examine 
the associations of 25(OH)D with MeS and its components. In 
the multivariate analyses, MeS and its individual components 
were treated as dependent variables (in a separate analysis) and 
serum 25(OH)D was treated as the independent variable. Serum 
25(OH)D was analyzed in three different forms: dichotomous 
(a cut-off value of 30 ng/mL), categorical using quartiles of 
25(OH)D levels, and continuous. A P-value of less than 0.05 
was considered statistically significant.
Results
Participants' characteristics
This study included a total of 3,234 adult individuals (776 men 
and 2458 women) who had complete data on all components 
of the MeS. Their age ranged between 19 and 90 years with 
a mean (SD) of 41.8 (13.3) years. The socio-demographic, Yousef S Khader et al. 135
Variables Gender
25-hydroxyvitamin D quartiles (ng/ml)*
P-value
Lowest Quartile Second quartile Third quartile Highest quartile
Waist circumference (cm) Men 93.6 (11.7) 93.2 (12.4) 91.4 (11.7) 91.9 (12.2) 0.210
Women 84.4 (14.0) 84.0 (14.8) 85.3 (14.7) 86.5 (15.9) 0.019
Body mass index (kg/m
2) Men 29.2 (5.1) 29.2 (5.5) 28.6 (4.8) 28.4 (4.5) 0.308
Women 29.8 (6.1) 30.0 (6.2) 30.4 (6.2) 31.1 (6.3)  0.001
Systolic blood pressure (mmHg) Men 127.8 (19.4) 125.4 (16.5) 124.4 (17.3) 125.6 (16.3) 0.269
Women 120.4 (16.3) 120.3 (16.1) 121.4 (16.3) 125.2 (17.9) < 0.005
Diastolic blood pressure (mm Hg) Men 82.2 (11.3) 80.7 (10.0) 81.2 (11.3) 82.4 (10.6) 0.351
Women 78.5 (9.9) 78.4 (10.1) 78.3 (9.5) 79.8 (10.2) 0.027
HDL Cholesterol (mg/dl) Men 35.2 (10.7) 34.5 (9.5) 36.6 (11.1) 35.3 (13.4) 0.304
Women 45.5 (12.8) 46.0 (12.8) 46.4 (13.9) 45.8 (14.0) 0.698
LDL Cholesterol (mg/dl) Men 114.6 (36.0) 111.5 (36.4) 117.4 (38.6) 114.4 (38.2) 0.488
Women 113.7 (38.1) 114.8 (37.3) 120.1 (37.6) 121.6 (37.9) < 0.005
Fasting blood sugar (mg/dl) Men 115.4 (66.3) 116.9 (70.2) 105.0 (43.8) 106.0 (51.4) 0.950
Women 95.1 (34.0) 95.8 (39.0) 100.6 (52.2) 106.8 (57.4) < 0.005
Triglycerides (mg/dl) Men 186.1 (96.8) 200.9 (112.7) 196.5 (112.1) 244.2 (198.9) < 0.005
Women 144.8 (80.8) 147.2 (84.7) 164.7 (110.4) 185.4 (127.0) < 0.005
Albumin (g/L) Men 44.2 (4.1) 44.3 (4.5) 44.8 (6.4) 44.5 (4.5) 0.550
Women 43.1  (5.3) 42.9  (4.4) 42.6  (4.6) 42.2  (4.7) 0.006
Calcium (mg/dl) Men 9.5 (0.6) 9.5 (0.6) 9.5 (0.6) 9.6 (0.6) 0.388
Women 9.3 (0.6) 9.3 (0.6) 9.4 (0.6) 9.5 (0.7) < 0.005
Phosphorus (mg/dl) Men 3.8 (0.9) 4.0 (1.4) 4.0 (1.1) 4.2 (1.5) 0.012
Women 3.9 (0.9) 4.1 (3.0) 4.2 (1.4) 4.3(1.5) < 0.005
Magnesium (mg/dl) Men 2.4 (0.3) 2.4 (0.4) 2.4 (0.4) 2.5 (0.5) 0.001
Women 2.3 (0.3) 2.3 (0.3) 2.4 (0.4) 2.4 (0.5) < 0.005
Creatinine (mg/dl) Men 0.9 (0.3) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2) 0.362
Women 0.6 (0.2) 0.6 (0.1) 0.6 (0.1) 0.7 (0.2) < 0.005
Parathyroid hormone (pg/ml) Men 24.4 (14.6) 22.5 (12.7) 22.1 (12.8) 19.2 (10.7) 0.001
Women 32.9 (23.3) 28.5 (18.8) 27.9 (18.2) 22.1 (12.0) < 0.005
* Lowest quartile (males: 25(OH)D ≤ 52.85, females: 25(OH)D ≤ 23.8); second quartile (males: 52.85 <25(OH)D ≤ 72.1, females: 23.8 < 25(OH)D ≤ 35.2); third quartile (males: 
72.1 < 25(OH)D ≤ 95.0,  females:  35.2 < 25(OH)D ≤50.6);  highest  quartile  (males:  25(OH)D > 95.0,  females:  25(OH)D > 50.6) 
Table 2. Anthropometric and clinical characteristics for Jordanian men and women according to quartiles of 25-hydroxyvitamin D (25(OH)D) 
anthropometric, clinical, and relevant characteristics of participants 
are shown in Table 1. Of the total, 42.0% (41.2% for men and 
42.3% for women) had MeS and 31.7% (6.3% for men and 39.7% 
for women) had 25(OH)D < 30 ng/ml. About 1.8% and 5.2% 
of the participants reported current use of vitamin D and calcium 
supplements, respectively, with no significant difference between 
those with and without metabolic syndrome. 
Anthropometric and clinical parameters according to quartiles 
of 25(OH)D levels 
Table 2 shows the differences in the anthropometric and 
clinical parameters across quartiles of 25(OH)D level for men 
and women. Among the men, there were significant differences 
in the averages for triglycerides, phosphorus, magnesium, and 
PTH levels across quartiles of 25(OH)D. The average for 
triglycerides was highest in the highest quartile of 25(OH)D level 
and the average for PTH was highest in the lowest quartile of 
25(OH)D. Among the women, there were significant differences 
in the averages of all studied anthropometric and clinical 
parameters across quartiles of 25(OH)D except in the average 
of HDL. The averages for LDL, fasting blood sugar, and 
triglycerides were highest in the upper two quartiles. The average 
PTH was highest in the lowest quartile. The differences in other 
parameters were small and were likely to be of marginal clinical 
significance.
25(OH)D and MeS
The age-standardized rate of MeS was 34.5.0% (95% confidence 
interval (CI): 31.0%-38.0%) for males and 40.5% (95% CI: 
38.5%-42.5%) for females. Bivariate analysis showed that 
subjects with low 25(OH)D levels had lower prevalence of MeS 
than subjects with normal 25(OH)D levels (38.2% vs. 43.8%, 
P-value = 0.003). However, in stratified analysis, the prevalence 
of MeS did not differ significantly between subjects with low 
and normal 25(OH)D levels for men and women in all age groups 
(Fig. 1). 
The lack of a significant difference in the prevalence of MeS 
between subjects with low and normal 25(OH)D was consistent 136 Vitamin D deficiency and metabolic syndrome
Fig. 1. The differences in the prevalence of metabolic syndrome between 
people with low and normal serum 25-hydroxyvitamin D level according to age 
and gender
Fig. 2. The differences in the prevalence of metabolic syndrome between 
people with low and normal serum 25-hydroxyvitamin D level according to body 
mass index category and gender
Table 3. Factors associated with metabolic syndrome in the multivariate 
analysis
Adjusted OR 
(95% Confidence Interval) P-value
Gender
Male  1.0
Female  1.10 (0.8, 1.4) 0.491
Age (year)
19-39 1.0
40-59  2.5 (2.1, 3.1)  < 0.005
≥60  4.4 (3.2, 6.2)  < 0.005
Education level
Illiterate  2.4 (1.6, 3.5)  < 0.005
< High school  1.6 (1.2, 1.9)  < 0.005
High school  1.1 (0.9, 1.4)  0.376
> High school  1.0
Marital status 
Single  1.0
Married  2.1 (1.5, 2.9) < 0.005
Region  
North  2.3 (1.6, 3.2)  < 0.005
Middle  1.5 (1.2, 1.9)  0.001
South  1.0
Hours of vigorous activity 0.98 (0.97 0.99) 0.042
Body mass index
Normal 1
Overweight 8.5 (5.7, 12.8)  < 0.005
Obesity 32.3 (21.6, 48.4)  < 0.005
Calcium (mg/dl)) 1.18 (1.02, 1.36)  0.025
Magnesium (mg/dl) 0.51 (0.39, 0.65)  < 0.005
Creatinine (mg/dl) 2.11 (1.17, 3.82)  0.013
Parathyroid hormone (pg/ml) 0.992 (0.986, 0.997)  0.002
Other  variables  were  tested  and  shown  to  be  non-significant
among normal weight, overweight, and obese adults when the 
subjects were stratified according to BMI/gender (Fig. 2) or 
when stratified according to BMI/age group. Furthermore, there 
were no significant differences in the age standardized rates of 
MeS between subjects with low and normal 25(OH)D levels 
(standardized rate ratio was 0.87 (95% CI: 0.45-1.40) for males 
and 0.91 (95% CI: 0.83-1.002) for females).
Multivariate analysis
In the multivariate analysis, the only variables that were 
significantly associated with MeS were age, educational level, 
marital status, region, body mass index, and serum levels of 
calcium, magnesium, creatinine, and PTH (Table 3). 
After adjusting for all significant variables in the model shown 
in Table 3, the odds of MeS were not significantly different 
between subjects with low and normal 25(OH)D levels (OR =
0.85, 95% CI: 0.70, 1.05, P-value = 0.133) (Table 4). The 
association between 25(OH)D and MeS remained non-significant 
when 25(OH)D was analyzed as a continuous variable (OR =
1.004, 95% CI; 1.000, 1.008, P-value = 0.057). There was no 
evidence of a sex interaction with 25(OH)D in all types of 
analysis. To explore a potential non-linear relationship between 
MeS and 25(OH)D, quartiles of 25(OH)D were implemented in 
an additional analysis that confirmed the absence of the association. 
Considering the association between 25(OH)D and the individual 
components of MeS, none of the individual components of MeS 
were significantly associated with 25(OH)D level in the multi-
variate analysis.
Discussion
Serum 25(OH)D level is the standard clinical measure of 
vitamin D status. Although a consensus regarding the optimal 
level of serum 25(OH)D has not yet been established, we chose 
a cut-off value of 30 to define vitamin D deficiency, to be 
consistent with the majority of experts who define the optimal 
level of 25(OH)D as ≥30 ng/ml (75 nmol/l) [41]. This level 
has been shown to be associated with maximal suppression of Yousef S Khader et al. 137
Dependent variable
Dichotomous independent variable
25-hydroxyvitamin D
(< 30 ng/ml vs. ≥30 ng/ml)
Continuous independent variable
25-hydroxyvitamin D 
(ng/ml)
OR 95% CI P-value OR 95% CI P-value
Metabolic syndrome (IDF)+  0.85 (0.70, 1.05) 0.133 1.004 (1.000, 1.008) 0.057
Central obesity  1.22 (0.97, 1.54) 0.093 1.001 (0.997, 1.005) 0.700
Raised fasting plasma glucose  0.95 (0.77, 1.18) 0.656 0.999 (0.996, 1.003) 0.710
Reduced HDL cholesterol  1.05 (0.88, 1.26) 0.577 0.998 (0.995, 1.002) 0.322
Raised triglycerides level  0.83 (0.69, 1.07) 0.120 1.005 (0.997, 1.009) 0.089
Raised blood pressure  1.008 (0.83, 1.22) 0.937 1.001 (0.998, 1.005) 0.533
* Adjusted  for  age,  gender,  marital  status,  education  level,  region,  hours  of  vigorous  activity,  body  mass  index,  calcium,  creatinine,  parathyroid  hormone,  and  magnesium 
levels
+ Central obesity (defined as waist circumference ≥ 94cm for men  and ≥ 80cm for women, with ethnicity specific values for other groups) plus any two of the following 
four factors: 1. Raised triglycerides level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatm ent for this lipid abnormality, 2. Reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L)
in males and <50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality, 3. Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm 
H g ,  o r  t r e a t m e n t  o f  p r e v io u s ly  d ia g n o s e d  h y p e r t e n s i o n ,  4 .  R a i s ed  fasting  plasma  glucose  (FPG)  ≥ 100  mg/dL  (5.6  mmol/L),  or  previously  diagnosed  type  2  diabetes 
Table 4. Multivariate analysis of the association between 25-hydroxyvitamin D and metabolic syndrome and its individual components*
PTH and reduced fracture rates and was postulated to be 
associated with better health outcomes [42,43]. 
Among the men and women, the univariate analysis showed 
significant differences in the averages of some clinical and 
anthropometric parameters across quartiles of 25(OH)D. However, 
the differences in these parameters were small and were likely 
of marginal clinical significance. Furthermore, these differences 
may have resulted from the effects of confounders. In the 
multivariate analysis, after adjusting for important variables 
including age, gender, marital status, education level, region, 
hours of vigorous activity, body mass index, and calcium, 
creatinine, PTH, and magnesium levels, there was no significant 
association between low 25(OH)D level and MeS. The associa-
tion remained non-significant when 25(OH)D level was used in 
its continuous form or when categorized based on the quartiles 
of 25(OH)D level.
The findings of previous cross-sectional studies [20-35] that 
explored the association between 25(OH)D and MeS are 
contradictory. Our finding of a lack of association between 
25(OH)D level and MeS is in agreement with findings of 
previous studies [31-34]. However, the majority of studies 
[21-30] have shown an inverse association between 25(OH)D 
level and MeS. The reasons behind the contradictory findings 
could be multiple, which makes the comparisons between studies 
difficult. Previous studies used different cut-off values to define 
insufficiency or deficiency of vitamin D, different definitions to 
define MeS, and used different statistical analysis strategies to 
analyze the data. During analysis, some authors used MeS as 
the dependent variable while others used 25(OH)D as the 
dependent variable. Some studies analyzed 25(OH)D as continuous 
and other studies analyzed it as dichotomous or as categorical 
based on quartiles or quintiles. 
In the multivariate analysis, the association between 25(OH)D 
and MeS was adjusted for important variables, including 
magnesium, calcium, and PTH. Not all previous studies adjusted 
in the multivariate analysis for important variables such as PTH 
and magnesium, which may at least partly explain the inverse 
association observed between vitamin D and MeS in other 
studies. Adjustment for such variables is extremely important 
because a close relationship exists between 25(OH)D, calcium, 
and PTH [34], to the extent that changes in the levels of any 
one of these biomarkers affects the levels of the others. A recent 
Swedish study of elderly men [44] showed that plasma PTH level 
was associated with a higher risk of cardiovascular mortality, 
even after adjustment for established cardiovascular risk factors 
and vitamin D deficiency. The effects of PTH and magnesium 
are of particular interest, as elevated levels of PTH and hypoma-
gnesemia have been reported together with MeS [24,33,35], and 
low serum magnesium levels have also been linked to insulin 
resistance [45]. The Medical Research Council Ely Prospective 
Study [46] showed that the inverse association between baseline 
25(OH)D levels and the MeS risk Z score was no longer 
significant after adjustments for PTH, calcium, and IGF-1.
Considering the association between 25(OH)D and individual 
components of MeS, 25(OH)D level was not significantly 
associated with individual components of MeS. Previous studies 
that explored the association between 25(OH)D and individual 
components of MeS showed inconsistent findings ranging from 
no association to inverse or positive associations. Studies that 
analyzed NHANES III data showed an inverse association 
between blood pressure and vitamin D concentration, even 
though it was not consistent across all different groups of 
subpopulations [47,48]. Other studies [49,50] did not show a 
significant association. The majority of cross-sectional and 
prospective studies in various populations have shown inverse 
associations between circulating 25OHD and fasting plasma 
glucose (FPG) [14,24,33], as well as triglyceride concentrations, 
especially in patients on hemodialysis, and various anthropometric 
measures. Some studies did not support such associations or 
reported discordance in the results depending on the population 
[14] and the measured outcomes.
One of the strengths of the present study is that the genera-
lizability of the study findings is enhanced by the selection of 
a nationally representative sample of Jordanian adults. However, 138 Vitamin D deficiency and metabolic syndrome
this study is limited by its cross-sectional design, which impairs 
causal inference due to the lack of temporality. Furthermore, only 
a single measurement of 25(OH)D was obtained. 
In conclusion, this study did not provide evidence to support 
the association between 25(OH)D levels and MeS or its 
individual components. Prospective studies are necessary to 
better determine the roles of 25(OH)D levels in the etiology of 
MeS.
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